GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Cyclically Adjusted Price-to-FCF

Betta Pharmaceuticals Co (SZSE:300558) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Betta Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Betta Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

Betta Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Betta Pharmaceuticals Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Betta Pharmaceuticals Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.251/115.1156*115.1156
=0.251

Current CPI (Mar. 2025) = 115.1156.

Betta Pharmaceuticals Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201512 0.000 100.600 0.000
201603 0.144 102.200 0.162
201606 0.120 101.400 0.136
201609 0.154 102.400 0.173
201612 -0.097 102.600 -0.109
201703 -0.096 103.200 -0.107
201706 -0.195 103.100 -0.218
201709 -0.283 104.100 -0.313
201712 -0.191 104.500 -0.210
201803 -0.193 105.300 -0.211
201806 -0.238 104.900 -0.261
201809 -0.180 106.600 -0.194
201812 -0.221 106.500 -0.239
201903 -0.290 107.700 -0.310
201906 -0.041 107.700 -0.044
201909 0.101 109.800 0.106
201912 0.061 111.200 0.063
202003 0.417 112.300 0.427
202006 -0.208 110.400 -0.217
202009 -0.324 111.700 -0.334
202012 0.020 111.500 0.021
202103 -0.253 112.662 -0.259
202106 0.008 111.769 0.008
202109 0.001 112.215 0.001
202112 -0.301 113.108 -0.306
202203 -0.594 114.335 -0.598
202206 -0.380 114.558 -0.382
202209 -0.650 115.339 -0.649
202212 -0.082 115.116 -0.082
202303 -0.392 115.116 -0.392
202306 -0.282 114.558 -0.283
202309 0.040 115.339 0.040
202312 0.206 114.781 0.207
202403 -0.156 115.227 -0.156
202406 0.313 114.781 0.314
202409 0.379 115.785 0.377
202412 -0.336 114.893 -0.337
202503 0.251 115.116 0.251

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Betta Pharmaceuticals Co  (SZSE:300558) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Betta Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 355, Xingzhong Road, Economic and Technological Development Zone, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311100
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co Headlines

No Headlines